Veracyte (VCYT) Revenue & Revenue Breakdown
Veracyte Revenue Highlights
Latest Revenue (Y)
$517.14M
Latest Revenue (Q)
$131.87M
Main Segment (Y)
Testing
Main Geography (Y)
UNITED STATES
Veracyte Revenue by Period
Veracyte Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $517.14M | 16.01% |
| 2024-12-31 | $445.76M | 23.46% |
| 2023-12-31 | $361.05M | 21.76% |
| 2022-12-31 | $296.54M | 35.09% |
| 2021-12-31 | $219.51M | 86.85% |
| 2020-12-31 | $117.48M | -2.40% |
| 2019-12-31 | $120.37M | 30.82% |
| 2018-12-31 | $92.01M | 27.87% |
| 2017-12-31 | $71.95M | 10.55% |
| 2016-12-31 | $65.08M | 31.48% |
| 2015-12-31 | $49.50M | 29.62% |
| 2014-12-31 | $38.19M | 74.51% |
| 2013-12-31 | $21.88M | 88.20% |
| 2012-12-31 | $11.63M | 339.62% |
| 2011-12-31 | $2.65M | - |
Veracyte generated $517.14M in revenue during NA 2025, up 16.01% compared to the previous quarter, and up 440.19% compared to the same period a year ago.
Veracyte Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $131.87M | 1.31% |
| 2025-06-30 | $130.16M | 13.71% |
| 2025-03-31 | $114.47M | -3.51% |
| 2024-12-31 | $118.63M | 2.39% |
| 2024-09-30 | $115.86M | 1.25% |
| 2024-06-30 | $114.43M | 18.16% |
| 2024-03-31 | $96.84M | -1.38% |
| 2023-12-31 | $98.20M | 8.98% |
| 2023-09-30 | $90.11M | -0.24% |
| 2023-06-30 | $90.32M | 9.58% |
| 2023-03-31 | $82.42M | 2.65% |
| 2022-12-31 | $80.30M | 6.22% |
| 2022-09-30 | $75.59M | 3.74% |
| 2022-06-30 | $72.86M | 7.50% |
| 2022-03-31 | $67.78M | 0.66% |
| 2021-12-31 | $67.34M | 11.54% |
| 2021-09-30 | $60.37M | 9.55% |
| 2021-06-30 | $55.10M | 50.14% |
| 2021-03-31 | $36.70M | 6.27% |
| 2020-12-31 | $34.54M | 10.97% |
| 2020-09-30 | $31.12M | 50.31% |
| 2020-06-30 | $20.70M | -33.47% |
| 2020-03-31 | $31.12M | 4.68% |
| 2019-12-31 | $29.73M | -4.01% |
| 2019-09-30 | $30.97M | 2.78% |
| 2019-06-30 | $30.14M | 2.06% |
| 2019-03-31 | $29.53M | 14.68% |
| 2018-12-31 | $25.75M | 9.73% |
| 2018-09-30 | $23.47M | 3.14% |
| 2018-06-30 | $22.75M | 13.52% |
| 2018-03-31 | $20.04M | 2.27% |
| 2017-12-31 | $19.60M | 11.86% |
| 2017-09-30 | $17.52M | -4.82% |
| 2017-06-30 | $18.41M | 12.01% |
| 2017-03-31 | $16.43M | -10.00% |
| 2016-12-31 | $18.26M | -1.86% |
| 2016-09-30 | $18.60M | 26.77% |
| 2016-06-30 | $14.68M | 8.30% |
| 2016-03-31 | $13.55M | 9.85% |
| 2015-09-30 | $12.34M | 3.59% |
| 2015-06-30 | $11.91M | 6.15% |
| 2015-03-31 | $11.22M | -8.04% |
| 2014-12-31 | $12.20M | 24.00% |
| 2014-09-30 | $9.84M | 13.38% |
| 2014-06-30 | $8.68M | 16.06% |
| 2014-03-31 | $7.48M | 9.33% |
| 2013-12-31 | $6.84M | 22.24% |
| 2013-09-30 | $5.59M | 10.38% |
| 2013-06-30 | $5.07M | 15.60% |
| 2013-03-31 | $4.38M | -1.64% |
| 2012-12-31 | $4.46M | 38.24% |
| 2012-09-30 | $3.22M | - |
Veracyte generated $131.87M in revenue during Q3 2025, up 1.31% compared to the previous quarter, and up 115.24% compared to the same period a year ago.
Veracyte Revenue Breakdown
Veracyte Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Testing | $493.15M | $418.96M | $250.54M | $58.86M | $101.97M |
| Product | $14.33M | $13.65M | $12.63M | $9.85M | - |
| Biopharmaceutical And Other | $9.66M | $13.15M | $33.36M | $19.87M | - |
| Biopharmaceutical | - | - | - | - | $5.67M |
| Collaboration | - | - | - | - | - |
Veracyte's latest annual revenue breakdown by segment (product or service), as of Dec 25: Testing (95.36%), Product (2.77%), and Biopharmaceutical And Other (1.87%).
Quarterly Revenue by Product
| Product/Service | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharmaceutical And Other | $686.00K | $1.09M | $4.30M | $3.58M | $7.01M | $3.14M | $3.00M | $18.92M | $4.56M | $6.13M | $6.80M | $7.70M | $10.04M | $8.82M | $11.16M | $6.51M | - | - | - | - |
| Product | $3.85M | $3.30M | $3.60M | $3.58M | $6.92M | $3.19M | $3.54M | $15.59M | $4.01M | $3.89M | $3.23M | $3.31M | $3.11M | $2.98M | $2.96M | $2.69M | $3.06M | $2.70M | $2.03M | - |
| Testing | $135.83M | $127.76M | $122.26M | $107.31M | $219.12M | $109.54M | $90.30M | $326.54M | $81.75M | $72.40M | $70.27M | $64.58M | $59.72M | $16.37M | $16.07M | $31.50M | - | - | - | - |
| Biopharmaceutical | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.62M | $566.00K | $343.00K | $824.00K |
| Collaborative | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Veracyte's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Testing (96.77%), Product (2.74%), and Biopharmaceutical And Other (0.49%).
Veracyte Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 25 | Dec 24 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| UNITED STATES | $496.60M | $423.54M | $262.92M | $200.98M | $109.61M |
| Non-US | $20.55M | $22.23M | $33.61M | $18.53M | $7.87M |
Veracyte's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (96.03%), and Non-US (3.97%).
Quarterly Revenue by Country
| Country | Dec 24 | Dec 23 |
|---|---|---|
| Non-US | $22.23M | $26.53M |
| UNITED STATES | $423.54M | $334.52M |
Veracyte's latest quarterly revenue breakdown by geography, as of Dec 24: UNITED STATES (95.01%), and Non-US (4.99%).
Veracyte Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| APLS | Apellis Pharmaceuticals | $689.38M | $177.75M |
| KNSA | Kiniksa Pharmaceuticals | $677.56M | $180.85M |
| FOLD | Amicus Therapeutics | $634.21M | $169.06M |
| VCYT | Veracyte | $517.14M | $131.87M |
| ZLAB | Zai Lab | $460.16M | $116.09M |
| TARS | Tarsus Pharmaceuticals | $451.36M | $118.70M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| ADPT | Adaptive Bio | $276.98M | $58.88M |
| IDYA | IDEAYA Biosciences | $218.71M | $207.83M |
| IRON | Disc Medicine | - | $7.91M |
| SRRK | Scholar Rock | - | - |